​

Candel Therapeutics Stock (NASDAQ:CADL)

ForecastOwnershipFinancialsChart
Candel Therapeutics by TradingView

Previous Close

$9.48

52W Range

$4.35 - $11.36

50D Avg

$8.86

200D Avg

$6.34

Market Cap

$558.89M

Avg Vol (3M)

$2.11M

Beta

-0.51

Div Yield

-

CADL Company Profile

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

55

IPO Date

Jul 27, 2021

Website

CADL Performance

CADL Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-48.27M$-33.37M$-38.39M
Net Income-$-55.18M$-37.94M
EBITDA$-48.27M$-52.10M$-37.43M
Basic EPS$-0.72$-1.74$-1.31
Diluted EPS$-0.72$-1.74$-1.31

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
CTNMContineum Therapeutics, Inc.
MREOMereo BioPharma Group plc
EDITEditas Medicine, Inc.
PRQRProQR Therapeutics N.V.
CAPRCapricor Therapeutics, Inc.
CABACabaletta Bio, Inc.
KYTXKyverna Therapeutics, Inc.
GNLXGenelux Corporation
ALDXAldeyra The
IMMPImmutep Limited